Entering text into the input field will update the search result below

Soligenix up 83% ahead of ricin vaccine data presentation

Apr. 19, 2017 10:31 AM ETSoligenix, Inc. (SNGX) StockBy: Douglas W. House, SA News Editor1 Comment
  • Thinly traded nano cap Soligenix (NASDAQ:SNGX +82.9%) jumps on a whopping 111x spike in volume ahead of a presentation next week on RiVax, its ricin toxin vaccine, at the 20th Annual Conference on Vaccine Research in Bethesda, MD. NY State Department of Health's Jennifer Yates, Ph.D., will be the presenter.
  • In preclinical testing, RiVax, formulated with the company's ThermoVax heat stabilization technology, demonstrated 100% protection in ricin aerosol challenge models.
  • The company says the data should support the FDA approval of RiVax under the "Animal Rule" which allows regulatory approval of certain drugs and biologics based on animal testing in situations where human testing is not possible or ethical.

Recommended For You

About SNGX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNGX--
Soligenix, Inc.